Fresenius Kabi Logo
  • Latest Biosimilars News
  • Contact Us
USA
Current website:
Fresenius Kabi Biosimilars
Suggested websites based on your location:
Fresenius Kabi USA - We Are Committed to Life
Global Website:
Fresenius Kabi Global Website

Fresenius Kabi around the world

  • Africa & Middle East
    • MENA
    • South Africa
  • Asia Pacific
    • Australia
    • China
    • China (Hong Kong SAR)
    • India
    • Indonesia
    • Japan
    • Korea
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • Taiwan
    • Thailand
    • Vietnam
  • Europe
    • Austria
    • Belgium
    • Croatia
    • Czech Republic
    • Denmark
    • Finland
    • France
    • Germany
    • Great Britain
    • Hungary
    • Ireland
    • Italy
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russian Federation
    • Slovakia
    • Spain
    • Sweden
    • Switzerland
  • Latin America
    • Argentina
    • Brazil
    • Chile
    • Colombia
    • Ecuador
    • Mexico
    • Peru
  • North America
    • Canada
    • USA
Fresenius Group
  • Why Fresenius Kabi
    • Main menu Why Fresenius Kabi

      Discover the history behind our areas of therapeutic expertise, patient-centric biosimilar development, state-of-the-art production, and rigorous testing.  

      • Our Advantage | Fresenius Kabi Our History

        Our commitment to deliver high-quality biosimilars is built on more than 100 years of expertise across numerous therapeutic areas. See what we have to offer today.

      • Our Advantage | Fresenius Kabi Patient-Centric Biosimilar Development

        We strive to ease the healthcare burden with affordable biologic medicine. Learn more about our biosimilar products.

      • Our Advantage | Fresenius Kabi State-of-the-Art Production

        We power our operations with dedicated commercial teams in various disciplines such as R&D, manufacturing and supply chain management.

      • Our Advantage | Fresenius Kabi Rigorous Testing

        Learn about the analytical methods we use to assess drug characteristics for biosimilarity between the biosimilar candidate and the reference product.

  • Our Portfolio of Biosimilars
    • Main menu Our Portfolio of Biosimilars

      Learn more about our approved biosimilar products in rheumatology, oncology, endocrinology, gastroenterology, and dermatology. Explore our biosimilars pipeline.

      • Our Biosimilar Portfolio Our Approved Products

        Our comprehensive portfolio of high-quality medicines has been developed with proven similarity in efficacy, safety, and immunogenicity to their reference products.

        • Our Approved Products Adalimumab-aacf

          Learn about the indications, biosimilarity to Humira® (adalimumab), dosing & administration, and patient support options. View information for patients & caregivers.

          • Adalimumab-aacf | Fresenius Kabi Totality of Evidence

            See the biosimilarity data for Adalimumab-aacf.

          • Adalimumab-aacf | Fresenius Kabi Dosing & Administration

            Read about how Adalimumab-aacf is administered and its dosage.

          • Adalimumab-aacf | Fresenius Kabi Support & Resources

            Discover patient assistance options to access Adalimumab-aacf. Download guides and brochures.

          • Adalimumab-aacf | Fresenius Kabi For Patients & Caregivers

            Understand how Adalimumab-aacf works. Learn about biosimilars. Download the patient and biosimilars brochure.

          • Adalimumab-aacf | Fresenius Kabi Important Safety Information

            Important Safety Information

          • Adalimumab-aacf | Fresenius Kabi Full Prescribing Information

            Full Prescribing Information

        • Our Approved Products BOMYNTRA® (denosumab-bnht)

          Learn about the indications, biosimilarity to Xgeva® (denosumab), dosing & administration, and patient support options. View information for patients & caregivers.

          • BOMYNTRA® (denosumab-bnht) Totality of Evidence

            See the biosimilarity data for BOMYNTRA.

          • BOMYNTRA® (denosumab-bnht) Dosing & Administration

            Read about how BOMYNTRA is administered and its dosage.

          • BOMYNTRA® (denosumab-bnht) Support & Resources

            Discover patient assistance options to access BOMYNTRA. Download guides and brochures.

          • BOMYNTRA® (denosumab-bnht) For Patients & Caregivers

            Understand how BOMYNTRA works. Learn about biosimilars. Download the patient and biosimilars brochure.

          • BOMYNTRA® (denosumab-bnht) Important Safety Information

            Important Safety Information

          • BOMYNTRA® (denosumab-bnht) Full Prescribing Information

            Full Prescribing Information

        • Our Approved Products CONEXXENCE® (denosumab-bnht)

          Learn about the indications, biosimilarity to Prolia® (denosumab), dosing & administration, and patient support options. View information for patients & caregivers.

          • CONEXXENCE® (denosumab-bnht) Totality of Evidence

            See the biosimilarity data for CONEXXENCE.

          • CONEXXENCE® (denosumab-bnht) Dosing & Administration

            Read about how CONEXXENCE is administered and its dosage.

          • CONEXXENCE® (denosumab-bnht) Support & Resources

            Discover patient assistance options to access CONEXXENCE. Download guides and brochures.

          • CONEXXENCE® (denosumab-bnht) For Patients & Caregivers

            Understand how CONEXXENCE works. Learn about biosimilars. Download the patient and biosimilars brochure.

          • CONEXXENCE® (denosumab-bnht) Important Safety Information

            Important Safety Information

          • CONEXXENCE® (denosumab-bnht) Full Prescribing Information

            Full Prescribing Information

        • Our Approved Products OTULFI® (ustekinumab-aauz)

          Learn about the indications, biosimilarity to Stelara® (ustekinumab), dosing & administration, and patient support options. View information for patients & caregivers.

          • OTULFI® (ustekinumab-aauz) Totality of Evidence

            See the biosimilarity data for OTULFI.

          • OTULFI® (ustekinumab-aauz) Dosing & Administration

            Read about how OTULFI is administered and its dosage.

          • OTULFI® (ustekinumab-aauz) Support & Resources

            Discover patient assistance options to access OTULFI. Download guides and brochures.

          • OTULFI® (ustekinumab-aauz) For Patients & Caregivers

            Understand how OTULFI works. Learn about biosimilars. Download the patient and biosimilars brochure.

          • OTULFI® (ustekinumab-aauz) Important Safety Information

            Important Safety Information

          • OTULFI® (ustekinumab-aauz) Full Prescribing Information

            Full Prescribing Information

        • Our Approved Products STIMUFEND® (pegfilgrastim-fpgk)

          Learn about the indication, biosimilarity to Neulasta®, dosing & administration and patient support options. View information for patients & caregivers.

          • STIMUFEND® (pegfilgrastim-fpgk) | Fresenius Kabi Totality of Evidence

            See the biosimilarity data for STIMUFEND.

          • STIMUFEND® (pegfilgrastim-fpgk) | Fresenius Kabi Dosing & Administration

            Read about how STIMUFEND is administered and its dosage.

          • STIMUFEND® (pegfilgrastim-fpgk) | Fresenius Kabi Support & Resources

            Discover patient assistance options to access STIMUFEND. Download guides and brochures.

          • STIMUFEND® (pegfilgrastim-fpgk) | Fresenius Kabi For Patients & Caregivers

            Understand how STIMUFEND works. Learn about biosimilars. Download the patient and biosimilars brochure.

          • STIMUFEND® (pegfilgrastim-fpgk) | Fresenius Kabi Important Safety Information

            Important Safety Information

          • STIMUFEND® (pegfilgrastim-fpgk) | Fresenius Kabi Full Prescribing Information

            Full Prescribing Information

        • Our Approved Products TYENNE® (tocilizumab-aazg)

          Learn about TYENNE® (tocilizumab-aazg), the first FDA-approved biosimilar for Actemra® (tocilizumab) made by Fresenius Kabi. See safety, dosing, and full prescribing info.

          • TYENNE® (tocilizumab-aazg) | Fresenius Kabi Totality of Evidence

            See the biosimilarity data for TYENNE.

          • TYENNE® (tocilizumab-aazg) | Fresenius Kabi Dosing & Administration

            Read about how TYENNE is administered and its dosage.

          • TYENNE® (tocilizumab-aazg) | Fresenius Kabi Support & Resources

            Discover patient assistance options to access TYENNE. Download guides and brochures.

          • TYENNE® (tocilizumab-aazg) | Fresenius Kabi For Patients & Caregivers

            Understand how TYENNE works. Learn about biosimilars. Download the patient and biosimilars brochure.

          • TYENNE® (tocilizumab-aazg) | Fresenius Kabi Important Safety Information

            Important Safety Information

          • TYENNE® (tocilizumab-aazg) | Fresenius Kabi Full Prescribing Information

            Full Prescribing Information

      • Our Biosimilar Portfolio Our Pipeline

        View our pipeline of biosimilars in the areas of immunology, oncology, hematology and endocrinology.

  • Patient Support & Access
    • Main menu Patient Support & Access

      See how we partner with healthcare providers and patients, and explore the benefits of our dedicated patient support program. 

      • Patient Support and Access | Fresenius Kabi Partnerships in Development & Treatment

        See who we work with to develop, manufacture and commercialize biosimilar products.

      • Patient Support and Access | Fresenius Kabi KabiCare Patient Support Program

        Our patient support program was developed with input from patients. Explore assistance options related to enrollment, insurance and therapy.

  • Resources
    • Main menu Resources

      Download guides, watch our videos and discover useful links.

Patient Support and Access


Partnerships in development and treatment

Fresenius Kabi has a strong network of external partners to ensure success across manufacturing, safety, and clinical operations while our key Account Managers partner with you to enable access and support.  
 



We seamlessly pair our products with innovative tools tailored to support healthcare providers and patients at every step of the treatment journey.  

KabiCare Patient Support Program

Through the Fresenius Kabi Patient Support Program, patients, caregivers, and healthcare providers have access to comprehensive support and resources throughout the treatment journey.  

Kabicare Patient Support Program

  • Why Fresenius Kabi
  • Our Portfolio of Biosimilars
  • Patient Support & Access
  • Resources
  • Latest Biosimilars News
  • Contact Us
Linkedin
  • Privacy Notice
  • Terms of Use
  • Data Privacy Contact
  • Cookie Notice
  • Imprint
  • Consumer Health Data Privacy Notice Supplement
  • Limit The Use of My Sensitive Personal Information
  • Accessibility Statement

© 2025 Fresenius Kabi USA, LLC. All Rights Reserved.
Adalimumab-aacf, BOMYNTRA, CONEXXENCE, OTULFI, STIMUFEND, TYENNE, and KABICARE are registered trademarks of Fresenius Kabi. Other trademarks are the property of their respective owners.
6059-BIOS-08-05/25 v1.0